MedPath
HSA Approval

POSACONAZOLE SANDOZ GASTRO-RESISTANT TABLETS 100MG

SIN15897P

POSACONAZOLE SANDOZ GASTRO-RESISTANT TABLETS 100MG

POSACONAZOLE SANDOZ GASTRO-RESISTANT TABLETS 100MG

March 9, 2020

NOVARTIS (SINGAPORE) PTE LTD

SANDOZ SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD
Licence HolderSANDOZ SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, DELAYED RELEASE

ORAL

Medical Information

J02AC04

posaconazole

Manufacturer Information

SANDOZ SINGAPORE PTE. LTD.

Catalent Pharma Solutions LLC

Lek Pharmaceuticals d.d. (Primary and Secondary Packager)

Active Ingredients

Posaconazole

100.00 mg

Posaconazole

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

POSACONAZOLE SANDOZ GASTRO-RESISTANT TABLETS 100MG - HSA Approval | MedPath